Recent studies found that the use of avapritinib (BLU285) to target these KIT or PDGFRA mutations showed significantly better antitumor effects than imatinib or regorafenib (Gebreyohannes et al., 2019), and avapritinib has been approved by the FDA for the treatment of inoperable or metastatic GIST with PDGFRA exon 18 mutation (Dhillon, 2020). This evidence concerns the gene KIT and gastrointestinal stromal tumor.